Fairvalue-Calculator Fairvalue-Calculator
EN DE

Eledon Pharmaceuticals, Inc (ELDN) Fair Value & Analysis

Healthcare · US · Market cap $303M

Price$3.95
Fair Value$4.73
Upside+19.7%
Quality95/100
Evidence: Low Range $3.55 – $5.91

Fair value as of: Jun 24, 2026

Analysis

Eledon Pharmaceuticals, Inc (ELDN) currently trades at $3.95, while our model-based Fair Value estimate is $4.73 — implying the stock looks roughly 19.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Eledon Pharmaceuticals, Inc (ELDN) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $4.73 versus a price of $3.95 — about +20% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ELDN?
Our 21-model fair value for Eledon Pharmaceuticals, Inc is $4.73 (as of Jun 24, 2026), built from audited fundamentals. The current price is $3.95.
What is the quality score of ELDN?
Eledon Pharmaceuticals, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.